Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Maternal epithelial ovarian cancer (EOC) is rare, and consequently, management strategies remain unclear due to the low incidence and paucity of reported data. Management depends on gestation, disease stage, future fertility desires, and the mother's wishes to continue pregnancy. Forty-one cases of maternal EOC were identified in the literature. Reporting of clinicopathological variables, treatment regimens, and follow up varied markedly. There are currently no definitive guidelines regarding the management of maternal EOC. Case reporting should contain detailed information on clinicopathological variables, treatment regimens, and maternal and neonatal outcomes. Data centralisation may be beneficial in identifying optimal management strategies in these rare tumours.

More information Original publication

DOI

10.1111/j.1471-0528.2008.02089.x

Type

Journal article

Publication Date

2009-03-01T00:00:00+00:00

Volume

116

Pages

480 - 491

Total pages

11

Keywords

Adult, Antineoplastic Agents, Female, Humans, Maternal Age, Middle Aged, Ovarian Neoplasms, Pregnancy, Pregnancy Complications, Neoplastic, Pregnancy Outcome, Young Adult